How the FDA Tracker Works

Last updated July 17, 2026 · sources checked daily · how this tracker works · RSS

Sources

• openFDA drug shortages database — current shortage status for semaglutide and tirzepatide, checked daily.
• openFDA drug enforcement reports — recalls involving GLP-1 products (posted weekly by FDA).
• FDA warning letters database — searched daily for GLP-1, semaglutide, tirzepatide, and compounding matches.
• FDA news feeds — press announcements, MedWatch safety alerts, and CDER drug updates, filtered for GLP-1 relevance.
• Federal Register — FDA rulemaking and notices mentioning GLP-1 drugs or compounding.
• Key FDA pages — we watch FDA's compounded-GLP-1 and compounding-policy pages and report when they change.

Editorial rules

• FDA facts are never altered — dates, counts, and the nature of every action come straight from the FDA document, which is linked on every item.
• Plain-English summaries are drafted with software assistance and reviewed by a human editor before publishing.
• Commentary appears only in clearly-marked “What this means” blocks, is never medical advice, and never goes beyond what the FDA document states about any company.
• We publish all relevant FDA actions — including enforcement against companies in the compounded GLP-1 space our reviews cover.

Update cadence

Sources are checked every morning. New items publish after human review, typically the same day. FDA content is a U.S. government work in the public domain; our summaries and commentary are our own.